Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab: Darzalex Continues To Impress, Epcoritamab One Step Closer To Market
09:45am, Wednesday, 30'th Nov 2022
Darzalex delivered strong growth in the third quarter, and Genmab increased the full-year guidance as a result. BLA submission for epcoritamab was accepted by the FDA and granted Priority Review.
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
12:29pm, Monday, 28'th Nov 2022 Zacks Investment Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potenti
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
02:10pm, Friday, 25'th Nov 2022
Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
02:40pm, Thursday, 24'th Nov 2022 Zacks Investment Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
11:15am, Tuesday, 22'nd Nov 2022 Zacks Investment Research
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
08:17pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
05:20pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
02:15pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
01:32pm, Thursday, 17'th Nov 2022
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
10:32am, Thursday, 17'th Nov 2022
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
04:40pm, Friday, 11'th Nov 2022 Zacks Investment Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 11'th Nov 2022
PBYI vs. GMAB: Which Stock Is the Better Value Option?
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
02:40pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
01:42pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
11:17am, Tuesday, 08'th Nov 2022
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
